These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 24880102)

  • 21. Oral anticoagulants and status of antidotes for the reversal of bleeding risk.
    Ebright J; Mousa SA
    Clin Appl Thromb Hemost; 2015 Mar; 21(2):105-14. PubMed ID: 25115762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific antidotes in development for reversal of novel anticoagulants: a review.
    Gomez-Outes A; Suarez-Gea ML; Lecumberri R; Terleira-Fernandez AI; Vargas-Castrillon E
    Recent Pat Cardiovasc Drug Discov; 2014; 9(1):2-10. PubMed ID: 25494843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
    Desai NR; Cornutt D
    Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prothrombin complex concentrates as reversal agents for new oral anticoagulants: lessons from preclinical studies with Beriplex.
    Dickneite G
    Clin Lab Med; 2014 Sep; 34(3):623-35. PubMed ID: 25168947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal agents for current and forthcoming direct oral anticoagulants.
    van Es N; De Caterina R; Weitz JI
    Eur Heart J; 2023 May; 44(20):1795-1806. PubMed ID: 36988142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome.
    Sciascia S; Lopez-Pedrera C; Cecchi I; Pecoraro C; Roccatello D; Cuadrado MJ
    Rheumatology (Oxford); 2016 Oct; 55(10):1726-35. PubMed ID: 26843482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies for urgent reversal of target-specific oral anticoagulants.
    Davis EM; Uhlmeyer EM; Schmidt DP; Schardt GL
    Hosp Pract (1995); 2014 Dec; 42(5):108-25. PubMed ID: 25485923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OKL-1111, A modified cyclodextrin as a potential universal reversal agent for anticoagulants.
    Meijers JCM; Bakhtiari K; Zwiers A; Peters SLM
    Thromb Res; 2023 Jul; 227():17-24. PubMed ID: 37207560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of novel oral anticoagulants in patients with major bleeding.
    Siegal DM; Cuker A
    J Thromb Thrombolysis; 2013 Apr; 35(3):391-8. PubMed ID: 23389753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of major bleeding for anticoagulated patients in the Emergency Department: an European experts consensus statement.
    Backus B; Beyer-Westendorf J; Body R; Lindner T; Möckel M; Sehgal V; Parry-Jones A; Seiffge D; Gibler B
    Eur J Emerg Med; 2023 Oct; 30(5):315-323. PubMed ID: 37427548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
    Enríquez A; Baranchuk A; Corbalán R
    Rev Med Chil; 2019; 147(1):73-82. PubMed ID: 30848768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Newer clinically available antithrombotics and their antidotes.
    Lévy S
    J Interv Card Electrophysiol; 2014 Sep; 40(3):269-75. PubMed ID: 24934756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants.
    Weitz JI; Pollack CV
    Thromb Haemost; 2015 Nov; 114(6):1113-26. PubMed ID: 26155974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in the development of specific antidotes for target-specific oral anticoagulants.
    Mo Y; Yam FK
    Pharmacotherapy; 2015 Feb; 35(2):198-207. PubMed ID: 25644580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversal of direct oral anticoagulants: a practical approach.
    Shih AW; Crowther MA
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current state of knowledge on oral anticoagulant reversal using procoagulant factors.
    Nitzki-George D; Wozniak I; Caprini JA
    Ann Pharmacother; 2013 Jun; 47(6):841-55. PubMed ID: 23695644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct oral anticoagulants: An update.
    Franco Moreno AI; Martín Díaz RM; García Navarro MJ
    Med Clin (Barc); 2018 Sep; 151(5):198-206. PubMed ID: 29295790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of direct oral anticoagulants.
    Zhang XY; Desborough MJ; Shapiro S
    Br J Hosp Med (Lond); 2017 Mar; 78(3):165-169. PubMed ID: 28277769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New oral anticoagulants: comparative pharmacology with vitamin K antagonists.
    Scaglione F
    Clin Pharmacokinet; 2013 Feb; 52(2):69-82. PubMed ID: 23292752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.